Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

ts with metastatic breast cancer receiving chemotherapy when administered to target a hemoglobin of greater than 12 g/dL;

-- increased the risk of death when administered to target a hemoglobin of 12 g/dL in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for this population.

(See WARNINGS: Increased Mortality and/or Tumor Progression in the prescribing information).

The Aranesp prescribing information, including important safety information and boxed warning, may be accessed at www.aranesp.com.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statement This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2006, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
(Date:7/29/2014)... , July 29, 2014  EnteroMedics Inc. (NASDAQ: ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 7, 2014 at ... the second quarter ended June 30, 2014 and to ... The second quarter conference call may be ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase federal ... to $5.8 billion next year, according to a new ... the Pharmaceutical Care Management Association (PCMA). Milliman projects that ... as 8.6 percent in 2015 as a result of ... The study finds that the majority of new ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... July 14, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... (SAB). The addition of Dr. Hannon, a researcher whose ... the microRNA pathway, increases SAB membership to six pioneers ...
... FRAZER, Pa., July 14, 2011 Cephalon, Inc. (Nasdaq: ... approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ... cash, or a total enterprise value of approximately $6.8 billion. ... Federal Trade Commission and the European Commission.  Cephalon and Teva ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5Cephalon Shareholders Approve Acquisition by Teva 2
(Date:7/29/2014)... July 30, 2014 Recent international ... devices have determined Nurse Call Systems to be ... this requires all Nurse Call Systems to be ... improves patient safety, reduces clinical risks, and is ... based Corporate Risk and Clinical Risk Committee actively ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip ... the program was actually created by a popular nutritionist ... He tried numerous treatments for this disorder, but none ... himself in the situation of having to look for ... of research. Dawson used this method, too, to become ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells are ... and effectiveness, according to a review in the August ... , the official medical journal of the American ... offer tremendous potential, but the marketplace is saturated with ... at risk," write Dr Michael T. Longaker of Stanford ...
(Date:7/29/2014)... According to a July 22, 2014 report ... Kim’s Butt to Angelina’s Lips: The Plastic Surgery Procedures ... celebrity feature most requested by women seeking cosmetic surgery. ... Jennifer Lawrence’s nose, and Angelina Jolie’s ... collected by an online community focused on plastic surgery ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Tylenol ... individuals who allegedly suffered serious liver injuries due ... move forward in a multidistrict litigation underway in ... Liebhard LLP reports. According to an Order dated ... deadlines pertaining to bellwether case and discovery issues. ...
Breaking Medicine News(10 mins):Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4
... can positively affect the human brain function, according to ... research, which was published in the journal NeuroImage ... environment impacts upon our brain functions. The ... such as the sea, cause distinct brain areas to ...
... 10 to 12 years younger than their white counterparts, according ... Neurology , the medical journal of the American Academy of ... the basis of 20 years of data, is among the ... disparities in health care, say Dr. Nicte Mejia and Dr. ...
... used to treat attention-deficit/hyperactivity disorder (ADHD) also provides ... that affect many childhood cancer survivors, according to ... Research Hospital investigators. Researchers reported that one ... survivors scored better on tests of sustained attention ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... Administration will ask an expert panel later this week whether ... to suspected heart risks. In documents released Monday ahead ... that members of its Endocrinologic & Metabolic Drugs Advisory Committee ...
... tests of mental aging reveals a good news-bad news situation. ... with age, to varying degrees. The good news is the ... to a study published by the American Psychological Association. ... and what,s called crystallized intelligence decline at older ages," said ...
... in which cells restrain beta-catenin and potentially suppress tumor ... small vesicles called exosomes. The study appears online on ... ( www.jcb.org ). Beta-catenin is a central ... proliferation and differentiation. Activation of the Wnt pathway stabilizes ...
Cached Medicine News:Health News:Study shows tranquil scenes have positive impact on brain 2Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 3Health News:FDA Panel to Mull Ban on Diet Drug Meridia 2Health News:FDA Panel to Mull Ban on Diet Drug Meridia 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3Health News:Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis 2
This design features a solid red iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: